CURE^® Lung Cancer 2022 Special Issue 1

April 18, 2022

An expert discusses the resources and support available to people to better face their end-of-life journey.

April 18, 2022

Activating mutations in this class of oncogenes, specifically KRAS, have made a big step forward scientifically and clinically just in the last couple of years.

April 16, 2022

Recent advancements surrounding the development of biomarker- targeted therapies have revolutionized the treatment of lung cancer.

April 14, 2022

Patients who are part of an advocacy group may be better equipped to understand biomarker testing during a lung cancer diagnosis and feel more empowered.

April 14, 2022

Over the past 20 years, advancements in the lung cancer space have led to a drastic paradigm shift in how patients are now treated, ultimately leading to substantial improvements in survival and patient quality of life.

April 13, 2022

The FDA’s recent approval of Opdivo plus chemotherapy may be beneficial for some patients with non-small cell lung cancer, further highlighting the need for multidisciplinary care.

April 13, 2022

Anti-TIGIT immunotherapy drugs may improve quality of life and survival, while being well tolerated by patients.

April 12, 2022

The KRAS G12C gene mutation in non-small cell lung cancer has been deemed “undruggable,” but recent effective therapies have successfully targeted this mutation, leading to shrinking of tumors and longer survival.

April 11, 2022

“It’s important for patients to be educated on (next-generation sequencing), because the more we know about a patient’s cancer, the better we can design a personalized treatment plan,” says an expert.